Novartis dumps worldwide rights to an Aveo drug, and the little biotech is not happy with them

Three years after Novartis stepped up and chipped in a $15 million upfront in a $326 million deal to partner with Aveo $AVEO on their drug to block GDF15, the pharma giant is retreating from the pact and dumping its alliance.